Last reviewed · How we verify
Tolerogenic Dendritic Cell Vaccine
At a glance
| Generic name | Tolerogenic Dendritic Cell Vaccine |
|---|---|
| Sponsor | City of Hope Medical Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes (PHASE1)
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis (PHASE2)
- A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS (PHASE2)
- A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tolerogenic Dendritic Cell Vaccine CI brief — competitive landscape report
- Tolerogenic Dendritic Cell Vaccine updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI